NEW YORK – Myriad Genetics said Wednesday that community-based public health initiative JScreen has signed a partnership around the use of Myriad's MyRisk with RiskScore hereditary cancer test and Foresight Carrier Screen reproductive health assay.
Under the agreement, JScreen will deliver its education and genetic care navigation program, while Myriad will contribute its genetic testing insights. Patients will be able to order a test kit through JScreen's online portal, after which they will then receive a saliva collection kit in the mail to send back to Myriad's lab for processing. Post-test consultations will be available to all patients to help them navigate their Myriad results.
Financial details were not disclosed.
Through this agreement, Myriad and JScreen hope to improve awareness, education, and testing convenience, in order to screen more people so that they and their doctor can understand their individual hereditary cancer or reproductive risks.
JScreen is a program based out of Emory University that's dedicated to preventing genetic diseases. The program's own carrier screening panel tests for over 200 disorders, many of which are common among Ashkenazi, Sephardi, and Mizrahi Jewish communities.
Myriad's collaboration with JScreen "is deeply rooted in our mutual commitments to prioritizing patient care and ensuring equitable access to high-quality genetic testing, which can help guide more informed medical decision-making and personalized care," Melissa Gonzales, president of Women's Health at Myriad, said in a statement.
Recently, Myriad also partnered with Flatiron Health on an initiative to enable physicians to order its MyRisk hereditary cancer test through Flatiron's cloud-based electronic medical record system.